DINESH

Fortis Healthcare

Industry: Healthcare
Latest CMP 770
Today's Change ▼ -6.33%
52-Week High / Low 1,097 | 770
Price Date: 30-Sep-2026
Recommendation Buy
Target Price 1,208
Expected Upside 25.2%
Forecast Horizon 2 Years
Historical CAGR 12.8%
1,000 Invested 09-May-2007
Today's Value 10,359
Investment Period 19 Years

Stock Snapshot

Post Results Return
-5.5%
Mild Negative Re-rating
1-Year Target Price
1,082
2-Year Target Price
1,208
52-Week High / Low
1,097 / 770
20-Day Return
-16.1%
Market Cap (Cr.)
58,132
Current PE
64.4
P/BV Ratio
5.9
Dividend Yield
0.2%
Industry PE
60.9

Price Performance

Vista Outlook

Basis of our Recommendation

Fortis Healthcare's recent management commentary highlights a robust growth trajectory, driven by a disciplined brownfield expansion strategy aimed at adding 1,800 beds by FY30 and a focus on high-margin clinical specialties such as oncology. Despite facing short-term margin pressures from ESOP-related costs and regulatory pricing caps, management remains optimistic about achieving a 25% EBITDA margin by FY28, supported by operational efficiencies and a strategic shift towards a higher-margin B2C diagnostic mix. Vista's financial outlook reflects a moderate revenue growth forecast, with stable margins anticipated, aligning with management's guidance of 15%+ revenue growth for FY27. The healthcare sector's overall growth, bolstered by increasing demand for organized tertiary care and rising insurance coverage, provides a favorable backdrop for Fortis. However, headwinds such as regulatory pressures and execution risks in integrating new facilities warrant close monitoring. Over the next 12-24 months, key opportunities include expanding the diagnostic footprint and enhancing operational efficiencies, while watchpoints include potential collection delays and the impact of pricing pressures on profitability

👍 Why We Like This Stock

  • Disciplined brownfield expansion strategy targeting 1,800 new beds by FY30
  • Focus on high-margin clinical specialties and operational efficiencies to drive EBITDA margins
  • Positive industry dynamics with increasing demand for organized healthcare services

⚠ Things To Watch Out For

  • Short-term margin pressures from ESOP costs and regulatory pricing caps
  • Execution risks associated with integrating new facilities and maintaining service quality
  • Potential collection delays from government and TPA channels impacting cash flow

Key Parameters

Balance Sheet Strength
Strong and Investable
Market Share
Stable
Industry Outlook
Weakening
Analyst View
Strong Buy
Dividend History
Regular
FII Holdings
Reducing

Financial Snapshot

View Technicals Analysis →
Actuals Forecast
FY24 FY25 FY26 FY27 FY28
Revenue (Cr.) 6,893 7,783 9,128 9,629 10,969
Profit Before Tax (Cr.) 838 1,093 1,388 1,483 1,869
PBT Margin 12.2% 14.0% 15.2% 15.4% 17.0%
Net Profit (Cr.) 676 893 1,081 1,157 1,428
Earnings Per Share 8.3 11.4 14.0 15.0 18.9

Analyst Recommendations

Broker Recommendation Target Price Date
HSBC ▲ Buy 1,100 07-Sep-2026
ICICI Securities ▲ Buy 1,075 07-Sep-2026
JPMorgan ▲ Overweight 1,180 07-Sep-2026
Jeffries ▲ Overweight 1,125 07-Sep-2026
Motilal Oswal ▲ Buy 1,130 07-Sep-2026
Nomura ► Neutral 1,030 07-Sep-2026
Prabhudas Liladhar ▲ Buy 1,050 07-Sep-2026
BofA ▲ Buy 1,070 10-Aug-2026
Citigroup ▲ Buy 1,180 10-Aug-2026
Goldman Sachs ► Neutral 975 10-Aug-2026
Geojit Financials ▲ Buy 1,150 16-Jun-2026
Choice Equity ▲ Buy 1,140 26-May-2026
Nuvama ▲ Buy 1,145 25-May-2026
Consensus Recommendation ▲ Strong Buy
Consensus Target 1,097
Coverage 13 Analysts
Analysts' Viewpoint
Fortis Healthcare's growth strategy focuses on aggressive brownfield expansion, aiming to add 1,800 beds by FY30, and enhancing operational efficiencies to improve margins. Analysts highlight the company's robust hospital segment performance and strategic shift towards higher-acuity procedures. Despite the Delhi High Court-mandated forensic audit creating a short-term stock price overhang, management asserts it will not impact current operations. Key risks include regulatory scrutiny and litigation, but potential catalysts such as IHH Healthcare's capital infusion and the integration of Gleneagles hospitals support long-term growth expectations.

Company Overview

Show Company Profile

Fortis Healthcare Limited operates as a healthcare delivery service provider in India. The company services in the areas of cardiac science, nephrology, diabetology/endocrinology, foetal medicine, infectious diseases, mental health and behavioral science, oncology, orthopedics, physiotherapy and rehabilitation, rheumatology, urology, nuclear medicine, critical care, emergency and trauma, general surgery, internal medicine, neurointerventional radiology, obstetrics and gynaecology, pediatrics, pediatrics, vascular surgery, and support facilities. It also provides services in the areas of infertility medicine, dental science, endocrine surgery, geriatric medicine, liver transplant and hepatobiliary sciences, neurology, ophthalmology, pain and palliative medicine, pulmonology, thoracic surgery, gastroenterology sciences, dermatology, ENT, haematology, medical generics, neurology, organ transplant, radiology, and transfusion medicines. In addition, the company offers various spectrum integrated healthcare services ranging from clinics to quaternary care facilities and a range of ancillary services, as well as secondary, and tertiary care services. The company's healthcare verticals comprise hospitals, diagnostics, and day care specialty facilities. Fortis Healthcare Limited was incorporated in 1996 and is based in Gurugram, India.